Murine myeloid leukemia: in vivo suppression by sericystatin A, a proteinase inhibitor from leukocytes.

Abstract

Parenteral administration of sericystatin A, an intracellular leukocyte inhibitor of the proinsulin-splitting enzyme cathepsin B, prolongs the mean survival time of mice with insulin-dependent myeloid leukemia. Sericystatin A reduces the supranormal blood levels of substances detectable by insulin-specific radioimmunoassay in these animals; this effect is abolished by concomitant insulin administration. It is concluded that sericystatin A reduces tumor proliferation indirectly, i.e. by reducing circulating insulin levels.

• Authors: K Pavelić, M Sirotković, M Kopitar, J Pavelić, S Vuk-Pavlović
• Journal: European journal of cancer & clinical oncology (Eur J Cancer Clin Oncol) Vol. 19 Issue 1 Pg. 123-6 (Jan 1983) ISSN: 0277-5379 [Print] England
• PMID: 6343090 (Publication Type: Journal Article)

Chemical References

• Csta1 protein, mouse
• Cystatin A
• Cystatins
• Insulin
• Protease Inhibitors
• Proteins
• Thymidine

Topics

• Animals
• Cells, Cultured
• Cystatin A
• Cystatins
• Insulin (blood, pharmacology)
• Leukemia, Experimental (drug therapy, metabolism, mortality)
• Leukemia, Myeloid (drug therapy, metabolism, mortality)
• Male
• Mice
• Mice, Inbred Strains
• Protease Inhibitors (therapeutic use)
• Proteins (antagonists & inhibitors, therapeutic use)
• Spleen (metabolism)
• Thymidine (metabolism)